All 2 tracked stories fall under one category: market-trends. GSK is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. That works out to roughly 0.1 stories per week across a 160-day span. They are less corroborated than the beat average, carrying 2 original sources each against 3.7 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Paul Bolno
All 2 tracked stories fall under one category: market-trends. GSK is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. That works out to roughly 0.1 stories per week across a 160-day span. They are less corroborated than the beat average, carrying 2 original sources each against 3.7 for the same window. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. We currently track 2 Healthcare stories that mention Paul Bolno, published between February 26, 2026 and August 4, 2026.
Stories tracked
2
Per week
0.1
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 906 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Paul Bolno. Shared-story counts are live from our verified record — not editorial picks.
Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
